# SHR-A1921

Source: https://onco.cc/drugs/shr-a1921/  
OnCo record `shr-a1921` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SHR-A1921 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for ovarian cancer, with its target not yet stated publicly.

## Summary

SHR-A1921 is an investigational agent whose form is not stated in the registry developed by Suzhou Suncadia Biopharmaceuticals and Shanghai Hengrui Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06394492 (SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer), in ovarian cancer. The largest, NCT06394492, plans to enrol 440 participants with primary completion was scheduled for 2026-05-31 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of SHR-A1921: https://clinicaltrials.gov/search?intr=SHR-A1921

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- trials: [A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06474455/), [SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer](https://onco.cc/trials/nct06394492/), [Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05765032/)

---
JSON: https://onco.cc/api/v1/entities/shr-a1921.json